Genentech, Inc.
1 DNA Way
South San Francisco
California
94080-4990
United States
Tel: 650-225-1000
Fax: 650-225-6000
Website: http://www.gene.com/
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1151 articles with Genentech, Inc.
-
A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.
-
Genentech to Present New Data from Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting
11/1/2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting
-
Phase III Data Showed That Venclexta Plus Gazyva Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
10/31/2018
The Phase III CLL14 study compared Venclexta in combination with Gazyva to standard-of-care Gazyva plus chlorambucil
-
Four former Genentech employees have been indicted by a federal grand jury for the alleged theft of company trade secrets in order to help a company set up in Taiwan develop drugs similar to those made by the Roche subsidiary.
-
Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of neovascular (wet) age-related macular degeneration (nAMD).
-
New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)
10/27/2018
Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ranibizumab for people with wet AMD1
-
Xofluza (baloxavir marboxil) was approved for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. The new medication has a novel mechanism of action that, Roche said, inhibits polymerase acidic endonuclease, an enzyme that is essential for the flu virus t...
-
Syros Pharma and Genentech: Corporate Culture Enhanced and Defined by Non-Work Activities
10/25/2018
What is presumably good humor, Cambridge, Mass.-based Syros Pharmaceuticals held its third annual Lab Olympics, where various executives in the company competed in a range of contests that included a race to put on safety equipment and accuracy in pipetting. -
Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza
10/24/2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Food and Drug Administration (FDA) has approved XOFLUZA™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older.
-
Mesothelioma is a rare cancer that develops in the lining of the lungs, abdomen, or cardiovascular cavity. A 2017 study reported that the number of people affected by this rare cancer is between 2,400 - 2,800 individuals per year in the United States alone.
-
Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
10/22/2018
The Phase III IMpower130 study investigating the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit
-
Updated with Exclusive | ESMO 2018: 60% of Ovarian Cancer Patients Receiving Lynparza Were Progre...
10/22/2018
AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer. -
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
-
Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors
10/21/2018
Entrectinib showed response irrespective of tumor type or spread to the central nervous system (CNS)
-
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
10/20/2018
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer
-
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
10/19/2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the Rituxan®
-
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
-
Immune Design Abandons Cancer Vaccine Program, Drops 20% of Workforce at Two U.S. Locations
10/18/2018
The company, with sites in Seattle and South San Francisco, focuses on next-generation oncology therapeutics. It recently completed a portfolio review and decided to focus its energies and existing capital on G100 and abandoned its CMB305 program. -
Two well-established pharma companies are expanding in two different U.S. cities. One city is known for the plethora of pharma and biotech jobs, while the other is in an area that might not immediately spring to mind when it comes to biotech hubs.
-
Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
10/15/2018
Phase III KATHERINE study shows Kadcyla® significantly improved invasive disease-free survival compared to Herceptin® in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment